berinert iv human c1 esterase inhibitor 500 iu powder for injection vial with diluent vial
csl behring australia pty ltd - water for injections, quantity: 10 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).
monofix-vf human coagulation factor ix 1000iu powder for injection vial and 10 ml diluent vial
csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, powder for - excipient ingredients: phosphate; plasma proteins; antithrombin iii; heparin sodium; sodium; citrate; chloride - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
monofix-vf human coagulation factor ix 500iu powder for injection vial and 5ml diluent vial
csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, powder for - excipient ingredients: citrate; heparin sodium; antithrombin iii; sodium; chloride; plasma proteins; phosphate - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
monofix-vf human coagulation factor ix 500iu powder for injection vial and diluent vial
csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in minor surgery, and as a prophylaxis in patients with haemophilia b. it has not been evaluated in major surgery. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels fo these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors. indications as at 14 may 1999: monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because is does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
berinert sc human c1 esterase inhibitor 3000 iu powder for injection glass vial with diluent vial
csl behring australia pty ltd - c1 esterase inhibitor, quantity: 3000 iu - injection, diluent for - excipient ingredients: - berinert? sc for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (hae) attacks in patients aged 8 years and older with c1 esterase inhibitor deficiency.
berinert sc human c1 esterase inhibitor 2000 iu powder for injection glass vial with diluent vial
csl behring australia pty ltd - c1 esterase inhibitor, quantity: 2000 iu - injection, diluent for - excipient ingredients: - berinert? sc for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (hae) attacks in patients aged 8 years and older with c1 esterase inhibitor deficiency.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 20 ml pre-filled syringe
csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
rhophylac 1500iu human anti-d immunoglobulin solution for injection syringe
csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 1500 iu - injection, solution - excipient ingredients: chloride; glycine; sodium; albumin - prevention of rh sensitisation in rh(d)-negative females at or below child-bearing age and treatment of rh(d)-negative persons after incompatible transfusions of rh(d)-positive blood or other products containing red blood cells.
biostate human coagulation factor viii 1000iu/ von willebrand factor 2400iu powder for injection vial with diluent vial
csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.
biostate human coagulation factor viii 500iu/ von willebrand factor 1200iu powder for injection vial with diluent vial
csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.